Earnings Call Summary | ELSE NUTRITION HOLDINGS INC(BABYF.US) Q1 2024 Earnings Conference
Earnings Call Summary | ELSE NUTRITION HOLDINGS INC(BABYF.US) Q1 2024 Earnings Conference
The company saw a 92% increase in U.S. Amazon sales and a 330% increase in Canadian Amazon sales compared to the same period in 2023.The following is a summary of the Else Nutrition Holdings Inc. (BABYF) Q1 2024 Earnings Call Transcript:
以下是Else Nutrition Holdings Inc.（BABYF）2024年第一季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
Else Nutrition Holdings reported a Q1 2024 revenue of $2.1 million, a drop from $2.9 million in Q1 2023.
Despite a decrease in the quarter revenue due to anticipated customer deal delays, the company expects to see significant revenue growth throughout 2024.
The company saw a 92% increase in U.S. Amazon sales and a 330% increase in Canadian Amazon sales compared to the same period in 2023.
Else Nutrition Holdings報告稱，2024年第一季度收入爲210萬美元，低於2023年第一季度的290萬美元。
儘管由於預期的客戶交易延遲，本季度收入有所下降，但該公司預計2024年全年收入將大幅增長。
與2023年同期相比，該公司在美國的亞馬遜銷售額增長了92％，加拿大亞馬遜的銷售額增長了330％。
Business Progress:
業務進展：
Else Nutrition started 2024 on a high note, with several retail partner announcements and launching their kids ready-to-drink shakes in both vanilla and chocolate flavors.
They are preparing to introduce an adult ready-to-drink line.
With the commercial launch of their plant-based infant formula in Australia, they are entering a growing market.
They have secured three manufacturing partners and signed a powder manufacturing agreement to guarantee supply through the end of 2025.
A new marketing program is underway to broaden brand recognition and fuel growth.
They are continually liaising with the FDA for U.S. approval based on the rising global demand for plant-based products.
Else Nutrition在2024年開局時表現強勁，宣佈了幾家零售合作伙伴，並推出了香草和巧克力口味的兒童即飲奶昔。
他們正準備推出成人即飲產品線。
隨着其植物性嬰兒配方奶粉在澳大利亞的商業推出，他們正在進入一個不斷增長的市場。
他們已經找到了三個製造合作伙伴，並簽署了粉末製造協議，以保證2025年底之前的供應。
一項新的營銷計劃正在進行中，以擴大品牌知名度並推動增長。
鑑於全球對植物基產品的需求不斷增加，他們一直在與美國食品藥品管理局聯絡，爭取美國的批准。
More details: ELSE NUTRITION HOLDINGS INC IR
更多詳情： 其他營養控股公司IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。
